Skip to content

Access to medicines reporting that holds up to the Index

A pharmacist advises a customer at a pharmacy counter.

A major pharmaceutical company asked us twice, two Index cycles apart, to check its Access to Medicine Index submission and show where its access strategy needed to go next.

The situation

The Access to Medicine Index ranks the world's largest pharmaceutical companies on how they make their products available in low- and middle-income countries. A major pharmaceutical company wanted its submission to reflect what it actually does for patients, and a clear view of where to strengthen its access strategy next.

What we did

Ahead of the 2024 Index we checked the draft submission against the methodology, claim by claim, and set out where the company's practice was strongest and where it could go further.

Two years later the company brought us back. By then the Index was asking a harder question: does a company manage patient reach systematically, with clear goals and transparent methods? We checked the new submission and built a roadmap for answering that question across the portfolio, starting from the areas where it already measured reach well.

What changed

Two submissions were tested against the methodology before they went in, and the company has a roadmap for how it plans, measures and reports patient reach. We helped our client move from a top 10 company to a top 5 company.

Preparing for the next Access to Medicine Index?

Janosch Jerman, CEO of Part of the Solution.

Janosch Jerman

Let's talk about how to manage and report patient reach with confidence.

Get in Touch

More to read

We look forward to hearing from you!

Contact us